Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at Mizuho

Autolus Therapeutics (NASDAQ:AUTL) had its price objective reduced by stock analysts at Mizuho from $12.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Several other analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright assumed coverage on shares of Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Friday. Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.80.

Autolus Therapeutics Stock Performance

AUTL stock opened at $1.36 on Tuesday. The stock has a fifty day moving average of $1.48 and a 200-day moving average of $1.52. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70. The company has a market capitalization of $360.62 million, a price-to-earnings ratio of -1.25 and a beta of 1.95.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $23.92 million. Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 87.75%. Equities analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors have recently made changes to their positions in AUTL. Mak Capital One LLC raised its holdings in shares of Autolus Therapeutics by 53.5% during the third quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock valued at $42,409,000 after acquiring an additional 9,062,518 shares in the last quarter. Armistice Capital LLC increased its position in Autolus Therapeutics by 9.1% during the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after purchasing an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd increased its position in Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after purchasing an additional 900,000 shares during the period. Cetera Investment Advisers raised its holdings in Autolus Therapeutics by 17.6% in the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after purchasing an additional 92,300 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Autolus Therapeutics in the 2nd quarter worth $1,288,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.